1834 Investment Advisors Co. Sells 95 Shares of Danaher Co. (NYSE:DHR)

1834 Investment Advisors Co. decreased its stake in shares of Danaher Co. (NYSE:DHR) by 5.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,612 shares of the conglomerate’s stock after selling 95 shares during the period. 1834 Investment Advisors Co.’s holdings in Danaher were worth $370,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Jamison Private Wealth Management Inc. increased its stake in shares of Danaher by 1.7% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 9,756 shares of the conglomerate’s stock worth $2,239,000 after purchasing an additional 159 shares during the period. First Citizens Bank & Trust Co. increased its position in Danaher by 1.4% during the 4th quarter. First Citizens Bank & Trust Co. now owns 40,422 shares of the conglomerate’s stock worth $9,279,000 after buying an additional 561 shares during the period. Investment Research & Advisory Group Inc. lifted its holdings in shares of Danaher by 3.4% during the fourth quarter. Investment Research & Advisory Group Inc. now owns 5,338 shares of the conglomerate’s stock worth $1,225,000 after buying an additional 177 shares in the last quarter. Duncan Williams Asset Management LLC boosted its position in shares of Danaher by 7.2% in the fourth quarter. Duncan Williams Asset Management LLC now owns 4,477 shares of the conglomerate’s stock valued at $1,028,000 after acquiring an additional 301 shares during the period. Finally, Affiance Financial LLC grew its stake in shares of Danaher by 54.4% in the fourth quarter. Affiance Financial LLC now owns 1,135 shares of the conglomerate’s stock valued at $169,000 after acquiring an additional 400 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.1 %

Shares of DHR opened at $245.95 on Monday. The stock has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a fifty day moving average of $235.33 and a 200-day moving average of $253.54.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analysts Set New Price Targets

Several brokerages have weighed in on DHR. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Raymond James reduced their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. TD Cowen upped their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Scotiabank assumed coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.